BidaskClub upgraded shares of Repligen (NASDAQ:RGEN) from a hold rating to a buy rating in a research report sent to investors on Saturday.

RGEN has been the topic of a number of other research reports. TheStreet lowered Repligen from a b- rating to a c rating in a research report on Monday, November 13th. CL King assumed coverage on Repligen in a research report on Monday, November 13th. They issued a buy rating and a $41.00 target price on the stock. Jefferies Group reissued a hold rating and issued a $40.00 target price on shares of Repligen in a research report on Thursday, October 19th. Zacks Investment Research lowered Repligen from a buy rating to a hold rating in a research report on Wednesday, October 11th. Finally, First Analysis raised Repligen from an equal weight rating to an overweight rating and set a $47.00 target price on the stock in a research report on Monday, October 2nd. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has a consensus rating of Buy and an average price target of $44.38.

Shares of Repligen (RGEN) opened at $37.06 on Friday. Repligen has a 1 year low of $28.48 and a 1 year high of $46.81. The stock has a market capitalization of $1,580.55, a P/E ratio of 62.81, a P/E/G ratio of 2.36 and a beta of 1.04.

Repligen (NASDAQ:RGEN) last announced its earnings results on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.04. Repligen had a return on equity of 7.57% and a net margin of 16.93%. The business had revenue of $36.58 million for the quarter, compared to analyst estimates of $35.69 million. During the same quarter last year, the firm earned $0.08 EPS. Repligen’s revenue for the quarter was up 48.2% compared to the same quarter last year. equities research analysts anticipate that Repligen will post 0.61 earnings per share for the current year.

In other Repligen news, VP Howard Benjamin sold 12,729 shares of the business’s stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $35.34, for a total transaction of $449,842.86. Following the transaction, the vice president now owns 36,554 shares of the company’s stock, valued at approximately $1,291,818.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.50% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the business. California Public Employees Retirement System increased its holdings in shares of Repligen by 1.6% during the 3rd quarter. California Public Employees Retirement System now owns 122,548 shares of the biotechnology company’s stock worth $4,696,000 after acquiring an additional 1,948 shares during the last quarter. Janney Montgomery Scott LLC acquired a new position in shares of Repligen during the 3rd quarter worth approximately $539,000. Cubist Systematic Strategies LLC increased its holdings in shares of Repligen by 113.7% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 23,288 shares of the biotechnology company’s stock worth $892,000 after acquiring an additional 12,388 shares during the last quarter. Perceptive Advisors LLC acquired a new position in shares of Repligen during the 3rd quarter worth approximately $3,349,000. Finally, Cornerstone Capital Management Holdings LLC. increased its holdings in shares of Repligen by 78.0% during the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 16,206 shares of the biotechnology company’s stock worth $620,000 after acquiring an additional 7,100 shares during the last quarter. 82.50% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Repligen (RGEN) Rating Increased to Buy at BidaskClub” was first reported by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2018/01/03/repligen-rgen-rating-increased-to-buy-at-bidaskclub.html.

About Repligen

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.